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Abstract
Background: Idiopathic Pulmonary Fibrosis (IPF) is an aggressive interstitial lung disease with an unpredictable
course. Occupational dust exposure may contribute to IPF onset, but its impact on antifibrotic treatment and
disease prognosis is still unknown. We evaluated clinical characteristics, respiratory function and prognostic
predictors at diagnosis and at 12 month treatment of pirfenidone or nintedanib in IPF patients according to
occupational dust exposure.
Methods: A total of 115 IPF patients were recruited. At diagnosis, we collected demographic, clinical characteristics,
occupational history. Pulmonary function tests were performed and two prognostic indices [Gender, Age,
Physiology (GAP) and Composite Physiologic Index (CPI)] calculated, both at diagnosis and after the 12 month
treatment. The date of long-term oxygen therapy (LTOT) initiation was recorded during the entire follow-up
(mean = 37.85, range 12–60 months).
Results: At baseline, patients exposed to occupational dust [≥ 10 years (n = 62)] showed a lower percentage of
graduates (19.3% vs 54.7%; p = 0.04) and a higher percentage of asbestos exposure (46.8% vs 18.9%; p 0.002) than
patients not exposed [< 10 years (n = 53)]. Both at diagnosis and after 12 months of antifibrotics, no significant
differences for respiratory function and prognostic predictors were found. The multivariate analysis confirmed that
occupational dust exposure did not affect neither FVC and DLCO after 12 month therapy nor the timing of LTOT
initiation.
Conclusion: Occupational dust exposure lasting 10 years or more does not seem to influence the therapeutic
effects of antifibrotics and the prognostic predictors in patients with IPF.
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Background
Idiopathic pulmonary fibrosis (IPF) is a chronic, progres-
sive, fibrosing interstitial pneumonia of unknown cause
defined by the histopathologic and/or radiologic pattern
of usual interstitial pneumonia (UIP) [1]. It appears
mainly in older adults and is associated with unrelenting
decline in lung function, advancing respiratory failure
and high mortality rate.
The possible involvement of occupational exposure
(past and/or still going) has been considered and investi-
gated with regards both to the pathogenesis and the pro-
gression of the disease. Previous observational studies
have implicated occupational exposures to metal, stone
and wood dust, chemical fumes and organic dust in the
pathogenesis of IPF and subjects exposed to these have
an increased risk of developing the condition [2, 3]. Al-
though a causal relationship between occupational
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exposure and IPF has not been recognized yet, the epi-
demiological evidence of occupations proved to be re-
lated to IPF is continuously growing [4]. Notably, males
with a history of heavy smoking and occupational expos-
ure to harmful agents, specifically birds and wood dust,
have been identified as a particular group at increased
risk of developing severe pulmonary fibrosis [5].
While the involvement of occupational and environ-
mental factors in the pathogenesis of IPF have been ex-
plored to a considerable extent, studies investigating
possible influence of job activity on the clinical features
and prognosis of this condition are few. Indeed, only one
report evaluated the clinical, physiologic and radiologic
characteristics and the prognosis in patients with IPF ac-
cording to their occupation. The main finding was that
dust-exposure occupation was significantly associated
with mortality after adjusting for major confounders
such as age, sex, lung function parameters and radiologic
aspects [6]. The little data available on the possible im-
pact of environmental factors on IPF prognosis shows
that both long-term exposure to and average concentra-
tion of ambient particulate (PM10 and PM2.5) are associ-
ated with overall mortality and an increase in the rate of
decline of forced vital capacity (FVC) in patients with
IPF [7, 8].
Investigations taking into account occupational and
environmental exposure in the assessment of the re-
sponse to antifibrotic therapy (pirfenidone and ninteda-
nib) in IPF patients are lacking.
Therefore, in this study we evaluated clinical and func-
tional characteristics at diagnosis and after 12 month
treatment in patients with IPF according to their occu-
pational dust exposure. In addition, we investigated if
such occupational exposure might influence the progno-
sis of IPF in terms of mortality and initiation to long-
term oxygen therapy (LTOT). In fact, although the latter
can vary from one physician to another, it indicates an
undoubted important worsening of the condition.
Methods
Study design and subjects
From January 2014 to December 2018 an observational
prospective cohort study was carried out. We enrolled
all consecutive patients (n = 115) referred to the Center
for rare lung disease of the University Hospital of Mod-
ena and to the Pneumological clinic of the Federico II
University Hospital of Napoli with a new diagnosis of
IPF. Diagnosis of IPF was performed according to the
2011 criteria of the American Thoracic Society/Euro-
pean Respiratory Society [1].
Data were registered in an ad hoc database. At base-
line, we collected for each patient socio-demographic
characteristics [age, sex, smoking status, amount smoked
(pack-years), educational level, lifetime occupational
history, exposure to asbestos] and clinical parameters
[body mass index (BMI), dyspnea, time of onset of re-
spiratory symptoms, comorbidities, pharmacological
treatment, disability perceived in relation to health con-
ditions and psychological distress]. We also recorded
pulmonary function tests (PFTs) and calculated the
prognostic indices Gender, Age, Physiology (GAP) and
the Composite Physiologic Index (CPI).
Of the 115 patients recruited, 101 were treated with
pirfenidone or nintedanib and of those 89 agreed to per-
form PFTs after 12 months of therapy. The study was
concluded when the last recruited patient completed the
12month treatment period.
All the 115 patients were censored for death and the
date of long-term oxygen therapy (LTOT) initiation for
the entire study period.
A written informed consent was provided by all partic-
ipants before recruitment. The study was conducted in
accordance to the Declaration of Helsinki and approved
by the institutional ethics committees of University Hos-
pitals of Ferrara, Modena and Napoli (N.160494).
Measurements
Sociodemographic and clinical features
BMI was calculated by dividing weight (Kg) by height
squared (m2). The number of pack years was figured as
number of cigarettes smoked per day x number of years
smoked/20. Level of dyspnea was assessed by the modi-
fied Medical Research Council (mMRC) scale. Disability
perceived in relation to health conditions and psycho-
logical distress were measured using the World Health
Organization Disability Assessment Schedule (WHO-
DAS) 12 items version [9] and the Hospital Anxiety and
Depression Scale (HADS) [10], respectively.
Occupational exposure
We collected a complete occupational history, including
a job activity checklist and a specific checklist of occupa-
tional dust exposure related to IPF (organic dusts; stone,
sand, or metal dusts; and wood dust) [6].
The recorded information included job title, tasks per-
formed, detailed description of the activity, use of indi-
vidual protection devices, substances contact, years
spent in each job and in each occupational dust expos-
ure. Occupational exposure was defined as occupational
exposure to dusts related to IPF by 10 or more years be-
fore diagnosis [5].
Lung function
PFTs were performed according to international criteria
[11]. To assess the possible influence of occupational ex-
posure on respiratory function and disease progression,
forced vital capacity percent of predicted (FVC % pred.)
and diffusing capacity of the lungs for carbon monoxide
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percent of predicted (DLCO % pred.) at diagnosis and at
12 month follow-up were used.
Prognostic predictors
Gender, Age, Physiology (GAP) index is a validated,
multidimensional tool that predicts mortality in IPF.
The calculation of the score encompasses gender (G),
age (A) and two lung physiology variables (P) (FVC %
pred. and DLCO % pred.). Points are assigned for
each variable to obtain a total range from 0 to 8. Ac-
cording to this score, patients are classified in stage I
(0–3 points), stage II (4–5 points), or stage III (6–8
points) [12]. As the GAP increases, the probability of
mortality rises.
Composite Physiologic Index (CPI) is a validated,
multidimensional index that correlates with the extent
of pulmonary fibrosis and mortality and thus predicts
IPF progression [13, 14]. CPI is computed as follows:
CPI = 91.0 - (0.65 × DLCO % predicted) - (0.53× FVC %
predicted) + (0.34 × FEV1% predicted). Higher CPI scores
indicate more severe fibrosis and poorer prognosis [14].
Both GAP and CPI index were calculated at diagnosis
and at 12 month follow-up, although GAP has not been
circumstantially validated at 1 year.
Initiation of long-term oxygen therapy (LTOT)
LTOT can be defined as oxygen used for at least 15 h
per day in chronically hypoxaemic patients [15]. In pa-
tients with IPF, LTOT initiation may be a marker of
poor prognosis as it predicts a median survival of less
than 18 months [13]. The date of long term oxygen initi-
ation was recorded for each participant.
Data analysis
IPF patients were classified according to exposure in two
groups: exposed (≥ 10 years) and not exposed (< 10
years).
First, at baseline, we investigated whether the two
groups differed in selected demographic variables, clin-
ical characteristics and lung functional parameters (FVC;
FEV1; DLCO; GAP and CPI index), using chi-squared
and Kruskal-Wallis tests for categorical and continuous
variables, respectively.
Second, we evaluated whether the two groups of pa-
tients differed in lung function measurements and prog-
nostic predictors measured after 12 month therapy.
Overall, a total of eight multiple regression models
were fit. However, as FVC and FEV1 at diagnosis were
highly collinear (Spearman rho = 0.96), only the analyses
related to FVC were reported to avoid redundancy.
In all models, covariates were included in a stepwise
forward process using the following criteria: clinical rele-
vance, with gender, age at symptoms onset, smoke and
occupational dust exposure forced to entry.
Occupational dust exposure was treated either as con-
tinuous or ordinal variable, including the above men-
tioned two groups of exposure (< 10 years and ≥ 10
years) as dummy variables.
The validity of final regression models was assessed as
follows: the assumption of constant error variance was
checked graphically, plotting Pearson residuals vs. fitted
values, and formally, using the Cook-Weisberg test for
heteroskedasticity. High leverage observations were
identified by computing Pearson, standardized and stu-
dentized residuals, and Cook’s D influence. In all
models, we found less than 10 high-leverage observa-
tions, excluding which we noted no substantial changes.
As a separate, additional evaluation, we tested with
Cox proportional hazard analysis whether there was any
evidence that starting oxygen therapy depended on: (a)
previous work exposure to dusts lasting ≥10 years; (b)
number of cigarette pack-years; (c) baseline FEV1; (d)
IPF stage at baseline (separately assessed using GAP and
CPI index). We selected all covariates a priori, and, in
order to avoid overfitting, we fitted two separate models,
each including one of the two IPF scoring systems, with
all other covariates remaining stable. Finally, we used
Schoenfeld’s test to check the validity of proportional
hazards assumption for both models.
Statistical significance was defined as a two-sided p-value<
0.05, and all analyses were carried out using Stata, version
13.1 (Stata Corp., College Station, Texas, USA, 2013).
Results
Baseline characteristics of the study population
Table 1 summarizes the baseline characteristics of the
115 study patients according to occupational exposure.
The mean duration of dust exposure related to IPF was
36.74 ± 13.75 and 1.2 ± 2.8 years in the exposed and not
exposed group, respectively. The majority of subjects
were male and current or former smokers with a similar
number of pack/years in the two groups. There was no
significant difference in age, age at respiratory symptoms
onset, the percentage of patients with family history of
IPF and with the distribution of the most common self-
reported comorbidities between IPF subjects with and
without occupational exposure. Likewise, dyspnea, classi-
fied according to the mMRC dyspnea score, the number
of subjects who did not start IPF treatment, those given
pirfenidone and those treated with nintedanib were simi-
lar in the two groups.
The exposed group counted a lower percentage of pa-
tients with an academic degree and a higher percentage
who reported asbestos exposure.
Pulmonary function tests and prognostic indices
No significant imbalance for pulmonary function param-
eters, including FVC % of the predicted and DLCO % of
Casillo et al. BMC Pulmonary Medicine          (2019) 19:170 Page 3 of 9
Table 1 Baseline demographic and clinical characteristics of the study population according to occupational dust exposure
Variablesa Exposed
(n = 62)
Not exposed
(n = 53)
p
Male gender, % 79.0 69.8 0.21
Mean age, years (SD) 69.6 (7.3) 68.7 (8.7)
Mean age at symptoms onset (SD) 68.2 (7.9) 67.7 (9.1)
Mean time-span between symptoms onset and diagnosis, months (SD) 15.7 (17.3) 17.8 (25.0)
Educational level, %
-Primary/secondary school 50.1 28.3
-High school 30.6 17.0
-University degree 19.3 54.7 0.04
Mean BMI, kg/m2 (SD) 28.0 (4.3) 28.1 (4.1)
Smoking status:
-Cigarette smoke (current or former), % 75.8 67.9
-Mean Pack/year (SD) 25.6 (24.0) 24.9 (27.8)
Comorbidities %
-None 11.3 3.8
-GERD 24.2 11.3
-Cancer 6.5 13.2
-Respiratory diseases 9.6 15.1
-Cardiovascular diseases 40.3 30.1
-Others 9.1 26.5
Family history of IPF, % 9.7 9.4
mMRC Breathlessness Scale gradeb, %
-Grade 0 4.8 9.3
-Grade 1 21.0 18.9
-Grade 2 32.3 43.4
-Grade 3 29.0 22.6
-Grade 4 12.9 5.7
Exposure to asbestos, % 46.8 18.9 0.002
Mean duration of asbestos exposure, years (SD) 8.9 (12.4) 5.8 (13.6)
Mean WHODAS 2.0 score (SD) 24.7 (18.6) 20.8 (19.2)
Mean HADS-A score (SD) 5.9 (3,2) 6.2 (3.5)
Mean HADS-D score (SD) 7.0 (3.1) 5.6 (3.4)
Pharmacological treatment, %
-None 16.1 7.6
-Pirfenidone 46.8 50.9
-Nintedanib 37.1 41.5
Exposed = occupational exposure to dust ≥10 years
Not exposed = occupational exposure to dust < 10 years
SD Standard deviation, BMI Body Mass Index, GERD Gastro-esophageal reflux disease, mMRC modified Medical Research Council, WHODAS 2.0 WHO Disability
Assessment Schedule 2.0 tool, HADS-A Hospital Anxiety and Depression Scale-Anxiety domain, HADS-D Hospital Anxiety and Depression Scale-Depression domain
aChi-squared test for categorical variables; Kruskal-Wallis test for normally-distributed and non normally distributed continuous variables, respectively. P-values
that are not reported were > 0.05. P-values < 0.05 are reported in bold
bEach grade of the mMRC Breathlessness Scale was scored as follows: Grade 0 = Not troubled by breathlessness except on strenuous exercise; Grade 1 = Short of
breath when hurrying on the level or walking up a slight hill; Grade 2 =Walks slower than most people on the level, stops after a mile or so, or stops after 15 min
walking at own pace; Grade 3 = Stops for breath after walking about 100 yards or after a few minutes on level ground; Grade 4 = Too breathless to leave the
house, or breathless when undressing
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the predicted, was found between the two groups
both at baseline and after 12 month therapy assess-
ment. Similarly, prognosis evaluated through GAP
graded score and CPI index was comparable in pa-
tients with and without occupational exposure
(Table 2, data are restricted to 89 subjects who
underwent pharmacological therapy and spirometry at
diagnosis and 12 month treatment visit). Dividing the
patients into three clinically meaningful groups ac-
cording to change in FVC after therapy ≥10%, < 10%
and stable/increased, we did not observe appreciable
differences with regards to neither the occupational
exposure nor the clinical or demographic features
[see Additional file 1].
Table 3 shows the results of a multivariate regres-
sion model for factors significantly related to FVC
and DLCO measured at 12 month treatment, after
adjusting for confounders. Male gender and 1 point
increase of FVC % pred. at baseline were significantly
associated with an increase of FVC % pred. After 12
months of treatment (p < 0.001). Likewise, 1 point in-
crease of DLCO % pred. at baseline was related to an
increase of DLCO % pred. After 1 year of therapy
(p < 0.001). Conversely, occupational exposure did not
affect neither FVC nor DLCO.
Initiation of long-term oxygen therapy (LTOT) and deaths
The mean follow-up was 37.85 (range 12–60) months.
Throughout this period 38 of the 115 patients (33%)
started LTOT. Comparing these subjects to those
who did not need LTOT, no significant difference for
occupational dust exposure was found (57.9% vs 52%;
with a mean duration of exposure of 23.7 ± 22.4 vs
18.8 ± 19.4, respectively). Patients receiving LTOT had
a higher baseline disability score (33.1 ± 21.1 vs 17.9 ±
15.5, p < 0.001), lower pulmonary function values
(FEV1, FVC, TLC and DLCO p < 0.002 for all) and
poor prognosis, as indicated by a higher GAP (4.2 ±
1.4 vs 3.6 ± 1.3, p = 0.02) and CPI index (52.0 ± 12.4
vs 43.2 ± 11.0, p < 0.001) calculated at baseline. Using
a Cox proportional hazard model, we explored poten-
tial predictors of LTOT initiation, in particular: work
exposure to dusts, cigarette pack/years, and baseline
FEV1, GAP and CPI index. Results are shown in
Table 4. Increasing FEV1 (L) reduces the risk to
undergo LTOT, whereas a higher GAP and CPI index
are predictive of LTOT initiation. Occupational dust
exposure was confirmed to be unrelated to LTOT.
The number of deaths was too small (n = 21, 18.2%) to
allow a proper statistical analysis. Patients died for pro-
gression or exacerbation of IPF (n = 11), cardiovascular
complications (n = 4), multiple organ failure (n = 3) and
cancer (n = 1). The cause of death was unknown for 2
patients due to lack of information.
Discussion
In this study, we have shown that 62 of the 115 patients
(54%) with a diagnosis of IPF had an occupational dust
Table 2 Pulmonary function parameters and prognosis indices according to dust exposure at baseline and 12month treatment
Variablesa Exposed
(n = 46)b
Not exposed
(n = 43)b
Baseline assessment 12-month assessment Baseline assessment 12-month assessment
Mean FEV1, L (SD) 2.2 (0.5) 2.1 (0.5) 2.1 (0.6) 2.1 (0.6)
Mean FEV1, % predicted (SD) 89.9 (21.2) 86.8 (19.9) 84.3 (20.3) 80.8 (19.2)
Mean FVC, L (SD) 2.6 (0.6) 2.5 (0.6) 2.5 (0.8) 2.4 (0.8)
Mean FVC, % predicted (SD) 84.0 (19.7) 80.5 (17.8) 76.7 (18.5) 73.7 (18.6)
Mean DLCO, % predicted (SD) 49.4 (14.7) 44.8 (18.0) 47.7 (12.2) 45.6 (13.3)
Mean TLC, L (SD) 4.5 (1.1) 4.3 (1.1) 4.2 (1.2) 4.1 (1.1)
Mean TLC, % predicted (SD) 76.1 (16.9) 71.4 (15.7) 71.8 (14.6) 67.6 (15.9)
GAP score, %
- 0–3 (IPF stage I) 40.9 31.8 40.5 36.6
- 4–5 (IPF stage II) 47.7 47.7 52.4 46.3
- 6–8 (IPF stage III) 11.4 20.5 7.1 17.1
Mean GAP score (SD) 3.8 (1.3) 4.0 (1.5) 3.7 (1.2) 4.0 (1.5)
Mean IPF stage (SD) 1.7 (0.7) 1.9 (0.7) 1.7 (0.6) 1.8 (0.7)
Mean CPI score (SD) 44.9 (12.3) 50.1 (15.1) 47.4 (9.9) 49.1 (11.1)
Exposed = occupational exposure to dust ≥10 years
Not exposed = occupational exposure to dust < 10 years
SD Standard deviation, FEV1 Forced Expiratory Volume at 1st second, FVC Forced Vital Capacity, DLCO Diffusing capacity of the lungs for Carbon Monoxide, TLC
Total Lung Capacity, GAP Gender, Age and Physiology, CPI Composite Physiologic Index
aChi-squared test for categorical variables; Kruskal-Wallis test for normally-distributed and non-normally distributed continuous variables, respectively. As all p-
values were > 0.05 they were not reported to avoid redundancy
bAnalysis restricted to 89 subjects in pharmacological treatment and with complete respiratory function tests at diagnosis and after 12 months of therapy
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exposure, defined as lasting 10 or more years. IPF pa-
tients with occupational dust exposure exhibited a lower
educational level and a higher frequency of reported as-
bestos exposure. Age, gender, smoking history, dyspnea,
comorbidities, lung function parameters and prognostic
indices (GAP, CPI) were similar in patients with and
without occupational exposure to dusts, both at diagno-
sis and after 12 month therapy with pirfenidone or nin-
tedanib. Occupational dust exposure did not seem to
influence the timing of initiation of LTOT in the follow-
up period.
The finding of a lower educational level in the dust-ex-
posed group was expected and corresponds to the re-
sults of other studies comparing the educational level
between workers exposed to various dusts and adminis-
tration office workers [16].
Also the higher percentage of IPF patients exposed to
asbestos in the dust-exposed group was not surprising.
Indeed, these two occupational exposures are often asso-
ciated with a number of work activities as carpentry, en-
gineering, construction and quarrying. In our study
population, asbestos exposure did not seem to affect
both clinical characteristics and lung function measure-
ments either before and after 12 months of IPF treat-
ment, indicating a careful exclusion of an asbestos
etiology in the diagnostic workup [17]. It is noteworthy
that the differential diagnosis between asbestosis and IPF
is challenging, and an accurate patient recall of historic
asbestos exposure is an essential factor in discriminating
the two conditions. In our study, of almost 50% of pa-
tients in the exposed group who had exposure to asbes-
tos, 17 had an occupational exposure, while the others
Table 3 Relationship between baseline characteristics of the population and FVC and DLCO at 12 month treatment
Variables FVC% pred.
1-year after treatment
DLCO% pred.
1-year after treatment
Adjusted coeff.
(95% CI)
p Adjusted coeff.
(95% CI)
p
Mean age at symptoms onset, 10-year increase −0.04 (− 0.12; 0.03) 0.2 0.17 (− 0.08; 0.43) 0.2
Male gender 0.44 (0.25; 0.63) < 0.001 3.11 (−3.45; 9.69) 0.3
Mean BMI, 10-point increase −0.08 (− 0.25; 0.09) 0.3 0.04 (− 0.52; 0.61) 0.9
Smoking status:
-Cigarette smoke, yes vs no 0.13 (−0.01; 0.27) 0.07 −1.34 (−5.62; 2.94) 0.5
-Mean pack/year, 10-unit increase −0.01 (− 0.04; 0.02) 0.5 − 0.15 (− 1.17; 0.88) 0.8
History of GERD, yes vs no 0.09 (− 0.06; 0.26) 0.3 0.98 (−4.61; 6.58) 0.7
Familiar history of IPF, yes vs no 0.00 (−0.21; 0.20) 0.9 2.75 (−3.84; 9.34) 0.4
Exposed vs not exposeda 0.06 (−0.06; 0.19) 0.3 1.17 (−3.01; 5.17) 0.6
Mean duration of exposure, 10-y increase −0.00 (− 0.03; 0.03) 0.9 − 0.01 (− 0.12; 0.09) 0.8
Asbestos exposure, yes vs no − 0.04 (− 0.17; 0.09) 0.6 −2.76 (− 7.25; 1.73) 0.2
FVC % predicted, 1% increase
-Baseline FVC 0.01 (0.01; 0.02) < 0.001 −1.96 (−6.47; 2.54) 0.4
-Pre-therapy FVC 0.02 (0.01; 0.02) < 0.001 −0.09 (− 0.23; 0.05) 0.2
DLCO % predicted, 1% increase
-Baseline DLCO 0.00 (−0.01; 0.01) 0.3 0.73 (0.52; 0.94) < 0.001
-Pre-therapy DLCO 0.00 (−0.00; 0.01) 0.5 0.71 (0.51; 0.91) < 0.001
mMRC Breathlessness Scale grade, 1-grade increase −0.01 (− 0.08; 0.06) 0.7 −1.31 (−3.57; − 0.95) 0.3
Analysis restricted to 89 subjects in pharmacological treatment and with complete respiratory function tests at diagnosis and after 12month of therapy. P-values < 0.05
are reported in bold
FVC Forced Vital Capacity, DLCO Diffusing capacity of the lungs for Carbon Monoxide, CI Confidence Interval, coeff. coefficient, BMI Body Mass Index, GERD Gastro-
esophageal reflux disease, mMRC modified Medical Research Council
aExposed = occupational exposure to dust ≥10 years, not exposed = occupational exposure to dust < 10 years
Table 4 Potential predictors of starting long term oxygen
therapy
Variables Oxygen therapy HR (95% CI) p
Exposed vs not exposeda 0.63 (0.28–1.40) 0.3
Mean pack/year, 10-unit increase 1.17 (0.98–1.39) 0.09
FEV1, L 1-unit increase 0.38 (0.17–0.85) 0.020
GAP score, 1-level increase 1.89 (1.30–2.76) 0.001
CPI score, 1-level increase 1.07 (1.02–1.12) 0.008
HR Hazard Ratio, CI Confidence Interval 95%, FEV1 Forced Expiratory Volume at
1st second, GAP Gender, Age and Physiology, CPI Composite Physiologic Index.
P-values < 0.05 are reported in bold.
aExposed = occupational exposure to dust ≥10 years, not exposed =
occupational exposure to dust < 10 years
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were exposed non-occupationally (household and neigh-
bourhood); of the non-exposed group only 3 had been
exposed in occupational settings. The estimated non-oc-
cupational exposure was not sufficient to support a diag-
nosis of asbestosis. Particular attention was paid in
investigating not only the timing but also the intensity of
asbestos exposure as a heavy exposure for few years may
be equivalent to a small exposure for many years. Con-
sidering time and intensity of exposure, the latter calcu-
lated approximately by job title and working history,
only a few patients in the exposed group had an asbestos
exposure that could support a diagnosis of asbestosis. As
patients suffering from asbestosis experience a better
survival rate than the general IPF population, we took
specific care to ascertain a correct differential diagnosis.
In subjects with a significant asbestos exposure, IPF were
diagnosed during a multidisciplinary dynamic discussion
after formal work-up, including extensive patient history,
chest radiograph and CT scan (also looking for benign
asbestos-associated pleural disease such as pleural pla-
ques, diffuse pleural fibrosis and benign asbestos pleural
effusion), but rarely searching for asbestos bodies in
BAL and lung tissue.
At the diagnosis, age, age at symptoms onset and lung
function parameters, particularly FVC % and DLCO % pre-
dicted, were found similar in patients exposed and not ex-
posed. These findings seem to disagree with those of Lee et
al. [6] who found an early onset of IPF and a reduced
DLCO in dust-exposed workers. However, they evaluated
occupational exposure differently: 1) medical and occupa-
tion records were collected retrospectively from a web-
based registry; 2) patients were categorized into five groups
according to occupations (unemployed or homemakers;
farmers, fishers or ranchers; sales or service personnel; cler-
ical or professional personnel; and workers exposed to
dusts, but excluding organic dusts); 3) an early onset of IPF
and a reduced DLCO were found significant when dust-ex-
posed workers were compared to unemployed or home-
makers but to none of the other group, making this result
rather weak.
As reported above, our patients exposed to occupa-
tional dust did not exhibit reduction in lung function pa-
rameters at the IPF diagnosis compared to those non
exposed. In population based studies, the issue of a pos-
sible effect of dust exposure at work on long-term excess
decline in lung function is still controversial. Indeed, the
results of previous reports are inconsistent and the dif-
ferences in study design, qualitative and quantitative
dust exposure and the lung function indices chosen as
outcome (FEV1, FVC, and/or FEV1/FVC) make them
even less conclusive. Lastly, smoking is a major injury
for lung function and, therefore, a crucial bias in the
evaluation of the lung effects of occupational dust
exposure [18].
Both pirfenidone and nintendanib have been shown to
lessen the decline in pulmonary function in patients with
IPF [19]. In particular, they reduce the number of patients
experiencing a decline in FVC of 10% or greater with the
result of slowing the disease progression, as compared to
no therapy [19]. Although we could not compare the rate
of disease progression between patients with and without
pharmacological treatment, we found that exposure to dust
at work does not seem to impact on the beneficial effect of
1 year pirfenidone and nintendanib. In fact, the stability of
lung function after 1 year of therapy was present in patients
with and without occupational dust exposure, and dust ex-
posure was not associated with post-treatment FVC % pred.
and DLCO % pred. Furthermore, the percentage of patients
with occupational dust exposure did not differ between
those who exhibited a decrease ≥10%, a decrease < 10% and
a stability or increase in pre-post therapy FVC % pred. To
our knowledge, this is the first study investigating the pos-
sible influence of occupational exposure to dusts on IPF
therapy, and it suggests that the beneficial effect of pirfeni-
done and nintendanib on lung function is not influenced by
the exposure to occupational dust.
In the present IPF patients, no difference was found in
GAP index score for IPF mortality, CPI and the percentage
of those who initiated LTOT based on dust exposure at
work. Whether occupational dust exposure could have an
impact on the prognosis of IPF patients is still unknown.
Lee et al. reported that exposure to dust was associated with
an increased risk of mortality in patients with IPF in a sur-
vival analysis where occupation was adjusted for age, sex,
pulmonary function, arterial partial pressure of oxygen
(PaO2), and honeycombing on the HRCT scan, but not in a
survival analysis where occupation was adjusted for GAP
stage [6], indicating that the question of a possible associ-
ation between occupational dust exposure and IPF progno-
sis remains unanswered.
In the present study also CPI was not related to dust
exposure, strengthening the result of GAP index score.
Interestingly, the relationship between CPI and occupa-
tional exposure in patients with IPF has not been previ-
ously investigated.
IPF patients who started LTOT during follow-up
showed lower levels of respiratory function (FEV1; FVC;
DLCO; TLC), worse prognostic indices (CPI; GAP) and
a higher level of disability at diagnosis compared to pa-
tients who did not start LTOT. Increased GAP score
and CPI at diagnosis were potential predictors of long-
term oxygen therapy initiation, whereas a higher level of
FEV1 was protective. Occupational exposure did not
affect LTOT. With regards to respiratory function pa-
rameters, our data confirm the results of previous stud-
ies that found an association between LTOT and low
levels of FEV1, FVC and DLCO in patients with pulmon-
ary fibrosis and other chronic lung diseases [20, 21].
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This observational study has some limitations. First,
occupational history was self-reported and, therefore,
potentially involving a recall bias. Data on measurements
of intensity of dust exposure at work, as well as the la-
tency between exposure cessation and disease diagnosis,
were not available. However, years of exposure were
gathered and the average of 36.74 years proves a consid-
erable exposure. Furthermore, as the intensity of dust
exposure generally differs between different occupations,
we divided our dust exposed group in two categories
based on data collected on job title: highest/heaviest dust
exposure and moderate dust exposure. Of the 46 ex-
posed, 50% had probable intense exposure (for example:
turners, construction workers, carpenters, textile
workers) and the remaining 50% moderate exposure (ex-
ample: cleaners, farmers, breeders). We did not find any
significant difference in spirometric parameters at diag-
nosis and at 12 months as well as in the number of
deaths and in the timing of initiation of LTOT between
the two categories of the exposed and between the high-
est/heaviest dust exposed compared with the non-ex-
posed (data not shown).
Second, complete data on lung function at diagnosis
and after 12 months were available for only 89 patients,
all under pharmacological treatment. Thus, given the ab-
sence of follow-up data for the group of untreated pa-
tients, it was not possible to comment on whether anti-
fibrotic treatment is effective in slowing disease progres-
sion/reduce the number of patients experiencing decline
in FVC > 10% regardless of dust exposure. Similarly,
there are no data to demonstrate that dust exposure
does not impact on the beneficial effect of anti-fibrotic
therapy at 1 year.
Third, the sample size of the study population was
relatively small to evaluate the exposure effect of each
occupational dust, i.e. organic dust, stone, sand, metal
and wood dust. Although this might have implicated an
underestimation of a specific kind of dust, we believe
that the investigation on occupational dust exposure in
its whole is particularly informative of the possible im-
pact of occupations on IPF prognostic predictors and
antifibrotic treatment. The limited sample size was also
responsible, at least in part, for the small number of
deaths we registered during the follow-up period and,
therefore, for the missed opportunity to perform a mor-
tality analysis. Nevertheless, we examined two well-rec-
ognized prognostic indices (GAP and CPI) and the
initiation of LTOT, another robust prognostic predictor,
contributing to address the question of the relationship,
if any, between occupational dust exposure and IPF
prognosis. It should be noted that available literature on
this issue at present is scarce and controversial [6, 22].
Finally, it has to be mentioned that GAP has been vali-
dated at diagnosis and not at 1 year. Nevertheless, we
thought we could calculate and report it since it has
been found that GAP models performed similarly in
diagnosis and in pooled follow-up visits [12].
Conclusions
IPF patients with occupational dust exposure have clinical
and functional characteristics similar to non-exposed IPF
patients at diagnosis. Also the effect of 12month antifibro-
tic therapy was found analogous in the two groups, irre-
spective of dust exposure. The prognostic indices, GAP
and CPI, and the timing of LTOT initiation did not appear
to be affected by such occupational exposure. Although
the results of our study were mainly negative, we believe
that it is worthy to explore each possible factor which may
influence the natural history and the response to therapy
of IPF, a disease associated to rapid progression, fast wors-
ening quality of life and high mortality.
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